Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GSK

- PMLiVE

GSK becomes first founding partner of global initiative tackling antimicrobial resistance

AMR could cause an estimated ten million deaths every year by 2050 unless action is taken

- PMLiVE

UK government launches five-year national action plan for antimicrobial resistance

It is estimated that 1.27 million global deaths in 2019 were caused by antibiotic-resistant infections

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

- PMLiVE

GSK’s shingles vaccine shown to maintain high protection in long-term study

The infectious condition affects up to one in three people globally in their lifetimes

- PMLiVE

UK scientists discover two genes offering potential drug targets against skin cancer

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

- PMLiVE

Scientists recommend new imaging technique to support design of innovative cancer drugs

Cryo-EM helped to determine the detailed structures of CAK, a promising target for cancer drugs

- PMLiVE

Gates Medical Research Institute initiates phase 3 study of tuberculosis vaccine candidate

According to WHO, the infectious disease was estimated to affect 10.6 million people in 2022

- PMLiVE

GSK’s Jemperli regimens demonstrate potential for wider endometrial cancer use

Approximately 417,000 new cases of endometrial cancer are reported globally every year

Can Cinderella save us?

University of Liverpool reveals new framework to tackle antimicrobial resistance in UK

AMR is designated by the World Health Organization as one of the top ten threats to global public health

- PMLiVE

GSK announces positive results for Blenrep in head-to-head multiple myeloma study

About 176,000 new cases of the blood cancer are diagnosed globally each year

- PMLiVE

GSK’s Jemperli combination recommended by NICE as first-line endometrial cancer treatment

Approximately 580 patients will now be eligible for treatment with the PD-1 inhibitor

- PMLiVE

First UK cancer patients receive Moderna’s experimental mRNA therapy

The Mobilize trial is evaluating mRNA-4359 in cancers including melanoma and lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links